|
Timothy R. Wright is president of pharmaceutical products and imaging solutions business segments of Tyco Healthcare, and founder of Mortimer Capital, an investment firm specializing in early-stage novel biologicals and small molecules. Mr. Wright is also chairman of ParagonRx, a privately held pharmaceutical risk management firm. He brings to Antigenics’ board 23 years of pharmaceutical industry experience in general management, product development and commercialization as well as business restructuring and transaction experience.
Prior to his current positions, Mr. Wright was chief operating officer of Xanodyne Pharmaceuticals, a privately held pharmaceutical company focused on pain management and women’s health, where he created and executed transition plans to build infrastructure in development, regulatory affairs and operations. Previously, he was president and interim CEO of AAI Pharma, a hybrid pharmaceutical, drug delivery/manufacturing, and global clinical research organization. Mr. Wright has also held senior management positions at Elan Bio-Pharmaceuticals, Cardinal Health Inc. and Dupont Merck Pharmaceutical Company. Mr. Wright has served on several boards of directors, including those for AAI Pharma and CeNes Pharmaceuticals. Mr. Wright earned his bachelor’s degree from The Ohio State University. | 